Date: 16th September 2022 Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen’s soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative […]
Author: E M
Research Scientist/Senior Research Scientist – Protein engineer and Protein chemist in Antibody drug discovery | 15.08.2022
Description Elasmogen Ltd is a multi-award-winning next generation therapeutic biologics company discovering and developing soloMERs™ for the treatment of oncology and autoimmune mediated inflammatory diseases. Currently located on the Foresterhill Health Campus, Aberdeen, and part of the city’s thriving biologics cluster, Elasmogen will be moving into the £40 million state-of-the-art Aberdeen life sciences BioHub also […]
BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen | 18.05.2022
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen […]
Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses | 17.12.2021
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new VNARs will not be immediately available as a treatment in people, but they […]
Elasmogen CEO Dr Caroline Barelle wins ‘Academic Entrepreneur of the Year’ award at Entrepreneurial Scotland’s Summit Awards 2018 | 26.11.2018
Elasmogen’s CEO Dr Caroline Barelle won the Academic Entrepreneur of the Year award at Entrepreneurial Scotland’s Summit Awards ceremony which took place on 22nd November 2018 in Glasgow. Commenting on her win, Caroline says “I am delighted to be recognised for championing science-led enterprise at a national level. It is a fantastic achievement, and there […]
Summit Awards – Celebrating Scottish Entrepreneurship | 16.10.2018
Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an individual who has demonstrated an enterprising approach to developing and delivering enterprise and entrepreneurial learning and skills, inspiring students and enabling them to realise their enterprise potential. The Academic to Entrepreneur […]
Almac Discovery, Elasmogen and Innovate UK Collaborate to Develop VNAR Based Oncology Platform | 06.08.2018
£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen, an SME focused on the development of next generation biologics, announced today that they have been awarded […]
Dr Caroline Barelle named “Rising Stars: Extraordinary Talent (2017)” at last night’s Scotland’s Life Sciences Dinner & Annual Awards. | 17.05.2018
17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising Stars: Extraordinary Talent (2017)” category at last night’s Scotland’s Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland’s top Life […]